XOMA ROYALTY CORPORATION
XOMANASDAQTrading Snapshot
- Day Range
- $39.55 – $40.34
- 52-Week Range
- $22.29 – $45.22
- Volume
- $2.13B
- Avg Volume
- $2.25B
- Shares Outstanding
- 17.7M
- Next Earnings
- Oct 26, 2026
Fundamentals Snapshot
- Annual Revenue
- $52M
- Last Q Revenue
- $12M
- P/E Ratio
- 21.0
- P/S Ratio
- 14.6x
- EPS (TTM)
- $2.00
- Dividend Yield
- 0.78%
- Dilution (1yr)
- +52.7%
Why Investors Own XOMA
- ✓High-growth profile — revenue up +57.1% YoY with expanding US Equity exposure.
- ✓Healthy economics — 28% gross margin and 6% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
XOMA ROYALTY CORPORATION
XOMA
StockOtter · stockotter.spaceAbout XOMA ROYALTY CORPORATION
XOMA Royalty Corp. functions as a specialist in aggregating biotechnology royalties, with its operations extending across Europe, the United States, and the Asia Pacific region. The company is dedicated to fostering advancements in human health by collaborating with biotechnology firms. Its core business model involves acquiring the anticipated future economic benefits, such as royalties and milestone payments, associated with pre-market therapeutic candidates that have already been licensed to pharmaceutical or biotechnology firms. The firm focuses its investments on early to mid-stage clinical assets, typically those in Phase 1 and 2 trials, selected for their robust commercial potential and because they are licensed to development partners. Its extensive portfolio currently encompasses around 70 distinct assets. The parent company, XOMA Corporation, established in 1981, has its main office in Emeryville, California.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
Ligand Pharmaceuticals Highlights XOMA-Fueled Royalty Growth, $700M in Deployable Capital
Ligand Pharmaceuticals NASDAQ: LGND outlined its royalty-focused growth strategy, recent XOMA acquisition and portfolio catalysts during a company presentation, highlighting a larger commercial-stage asset base and plann
Dimensional Fund Advisors LP Boosts Stock Holdings in XOMA Royalty Corporation $XOMA
Dimensional Fund Advisors LP grew its holdings in XOMA Royalty Corporation (NASDAQ: XOMA) by 207.7% during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Co
Ligand Completes Acquisition of XOMA Royalty, Creating a Portfolio of More than 200 Biopharmaceutical Royalty Assets
Acquisition adds seven commercial products including VABYSMO® (faricimab-svoa), OJEMDA™ (tovorafenib), and MIPLYFFA® (arimoclomol), and more than 100 development and commercial-stage assets, creating long-term opportuni
XOMA Royalty Announces Closing of Its Acquisition by Ligand
EMERYVILLE, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation today announced that Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) has completed its previously announced acquisition of XOMA Royalty.